ALLGENESIS Trademark

Trademark Overview

On Wednesday, January 3, 2018, a trademark application was filed for ALLGENESIS with the United States Patent and Trademark Office. The USPTO has given the ALLGENESIS trademark a serial number of 87741560. The federal status of this trademark filing is REGISTERED as of Tuesday, March 26, 2019. This trademark is owned by Allgenesis Biotherapeutics Inc.. The ALLGENESIS trademark is filed in the Pharmaceutical Products category with the following description:

Medicines for the treatment of ophthalmic and central nervous system (CNS) diseases for human purposes; Diagnostic test reagents for medical purposes
allgenesis

General Information

Serial Number87741560
Word MarkALLGENESIS
Filing DateWednesday, January 3, 2018
Status700 - REGISTERED
Status DateTuesday, March 26, 2019
Registration Number5707152
Registration DateTuesday, March 26, 2019
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 23, 2018

Trademark Statements

Goods and ServicesMedicines for the treatment of ophthalmic and central nervous system (CNS) diseases for human purposes; Diagnostic test reagents for medical purposes

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, January 17, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAllgenesis Biotherapeutics Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSongshan Dist., Taipei 105
TW
Party NameAllgenesis Biotherapeutics Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSongshan Dist., Taipei 105
TW
Party NameAllgenesis Biotherapeutics Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSongshan Dist., Taipei 105
TW

Trademark Events

Event DateEvent Description
Thursday, April 19, 2018NON-FINAL ACTION WRITTEN
Saturday, January 6, 2018NEW APPLICATION ENTERED
Wednesday, January 17, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, April 12, 2018ASSIGNED TO EXAMINER
Thursday, April 19, 2018NON-FINAL ACTION E-MAILED
Thursday, September 6, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, April 19, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, April 20, 2018UNDELIVERABLE MAIL - COURTESY COPY MAILED
Thursday, May 3, 2018TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, June 12, 2018TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, June 12, 2018ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, September 17, 2018ASSIGNED TO LIE
Monday, September 17, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, September 17, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, September 17, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, September 20, 2018LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, October 3, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, October 23, 2018PUBLISHED FOR OPPOSITION
Tuesday, October 23, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 18, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 15, 2019TEAS DELETE 1(B) BASIS RECEIVED
Friday, February 15, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, February 6, 2019TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, February 6, 2019NOTICE OF ALLOWANCE CANCELLED
Tuesday, March 26, 2024COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Friday, February 15, 20191(B) BASIS DELETED; PROCEED TO REGISTRATION
Tuesday, March 26, 2019REGISTERED-PRINCIPAL REGISTER
Friday, September 27, 2024TEAS SECTION 8 RECEIVED

Related Keywords

allgenesis purposes diagnostic test reagents medical human diseases ophthalmic treatment central